NeuroSearch to present at the UBS Global Life Science Conference in New York

Investor News


NeuroSearch to present at the UBS Global Life Science Conference in New York

NeuroSearch (NEUR) will present at the UBS Global Life Science Conference to be
held from 24-27 September in New York. 

The presentation will be held by Flemming Pedersen, CEO, and is scheduled for:

Wednesday 26 September 2007 at 8:30 am (EST).

As part of the presentation, Flemming Pedersen will inform about the
breakthrough results recently obtained by NeuroSearch in a Phase IIb
Proof-of-Concept study with the drug candidate tesofensine for the treatment of
obesity (see announcement of 17 September 2007). 

A PowerPoint version of the presentation will be accessible on our website
www.neurosearch.com just prior to the presentation at the conference. 



Contact person: 
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications 
Telephone: +45 4017 5103



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the
OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of
novel drugs, based on a broad and well-established drug discovery platform
focusing on ion channels and CNS disorders. A substantial part of the company's
activities are partner financed through a broad alliance with GlaxoSmithKline
(GSK) and collaborations with among others Abbott and Astellas. The drug
pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in
Huntington's disease (in preparation for Phase III), tesofensine in
obesity/type 2 diabetes (Phase II), NS2359 in depression (Phase II) and ADHD
(Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II),
ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott,
ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in
bipolar disorder (Phase I) and ABT-107 as well as ABT-560 for the treatment of
various CNS diseases - both (Phase I) in collaboration with Abbott. In
addition, NeuroSearch has a broad portfolio of preclinical drug candidates and
holds equity interests in several biotech companies.